FDA Approves New Sunscreen Ingredient Bemotrizinol for U.S. Market

The U.S. Food and Drug Administration (FDA) approved the chemical compound bemotrizinol for over-the-counter (OTC) sunscreen use in the United States, marking the first new active ingredient approved since 1999, according to FDA records. The decision, announced on June 9, 2026, follows decades of use in Europe and Asia, where it has been marketed as a broad-spectrum UV filter.

What Is Bemotrizinol and How Does It Work?

Bemotrizinol is a synthetic organic compound designed to absorb ultraviolet (UV) light. It functions as a chemical sunscreen, meaning it absorbs UV rays and converts them into heat, rather than reflecting them like mineral sunscreens such as zinc oxide or titanium dioxide. According to the European Commission’s Scientific Committee on Consumer Safety (SCCS), bemotrizinol effectively blocks both UVA and UVB rays, offering broad-spectrum protection.

Unlike some chemical sunscreens that degrade quickly in sunlight, bemotrizinol is described as photostable, meaning it maintains its protective properties for longer periods. The FDA’s approval highlights its potential to reduce the frequency of reapplication, though users are still advised to follow standard sunscreen guidelines, including reapplication every two hours.

Why Is This Approval Significant?

The last approved sunscreen ingredient in the U.S. was avobenzone in 1999, according to the FDA. Over the past two decades, consumer demand for more effective and stable UV protection has grown, prompting calls for new options. The approval of bemotrizinol addresses this need, offering a formulation that combines UVA and UVB protection without requiring additional ingredients.

Dr. Natalie Singh, a board-certified internal medicine physician and health editor, explained that bemotrizinol’s molecular structure allows it to remain on the skin’s surface rather than being absorbed into the bloodstream. “This could alleviate concerns about systemic absorption, though more research is needed to confirm long-term safety,” she said.

How Does Bemotrizinol Compare to Existing Sunscreens?

Traditional chemical sunscreens often require a combination of ingredients to achieve broad-spectrum protection. For example, avobenzone is commonly paired with octinoxate or octocrylene to enhance stability. Bemotrizinol, by contrast, is designed to function as a standalone UVA filter, simplifying formulations.

Mineral sunscreens, which use zinc oxide or titanium dioxide, work by physically blocking UV rays. While effective, they can leave a white residue on the skin. Bemotrizinol, as a chemical filter, is typically formulated to be more transparent, though its performance in real-world conditions remains under evaluation.

What Are the Potential Benefits and Concerns?

The FDA’s approval emphasizes bemotrizinol’s photostability, which may reduce the need for frequent reapplication. However, the agency also noted that users should still adhere to standard sunscreen practices, such as applying generously and reapplying after swimming or sweating.

Some dermatologists have raised questions about the long-term effects of chemical sunscreens, including potential endocrine disruption. While the SCCS concluded that bemotrizinol is safe at approved concentrations, the FDA has not yet released detailed safety data. “More studies are needed to assess its impact on human health, particularly with prolonged use,” said Dr. Singh.

What’s Next for Sunscreen Innovation?

The approval of bemotrizinol reflects ongoing efforts to improve UV protection. Researchers are also exploring alternatives, such as natural UV filters and advanced delivery systems. The FDA has indicated it is reviewing other potential ingredients